The market cap is only 10 million right now. So it doesn't need to be a cure to have further upside IMO. As for the benefits or lack thereof from the treatment, I don't know how to ferret that out from the study they did. It's not great that it lacked a control group, but on the other hand, it was stated that COPD would normally be progressively degenerative and improvement was observed instead of degeneration, so that may mean that simply a lack of the pulmonary function worsening is already a substantive benefit. I'm not a medical expert so I don't know, just saying what seems plausible from my uneducated vantage point.
News 
Market Data 
Discover 
